A FormBlends network publication
FormBlends Video Library

Playlist: Tirzepatide

Four videos on the dual GIP and GLP-1 agonist: a journal summary of an off-label study, a specialist journal club, a conversation with a SURPASS investigator, and a head-to-head with semaglutide from a diabetes nonprofit.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

Playlist player

Open full calculator

Tirzepatide: 4 videos, about 76 minutes in total. Watch in order; each write-up assumes the ones before it.

  1. 1 of 4 · 3:44

    Effect of Tirzepatide on Body Weight & Diabetes Control

    Mayo Proceedings · Original

    Two Mayo Clinic research fellows summarise their Mayo Clinic Proceedings paper: in adults with type 1 diabetes and overweight or obesity treated with tirzepatide, mean weight loss of 8.5 percent at a median 8 months and 12 percent at 12 months, a 1 percentage-point A1c fall and a 31.6 percent drop in insulin requirement.

    Read the full fact-check

  2. 2 of 4 · 48:11

    EFL021 - Metabolic Effects of a Dual GIP and GLP-1 RA

    Endocrine Society · Original

    An Endocrine Society journal club on a JCEM metabolomics analysis of a 26-week phase 2 trial against dulaglutide and placebo: tirzepatide lowered branched-chain amino acids and their catabolites, 2-hydroxybutyrate and several triglyceride and diglyceride species in a dose-dependent way, changes that correlated with insulin-sensitivity markers.

    Read the full fact-check

  3. 3 of 4 · 16:44

    Interpreting the Data with Tirzepatide

    Cardiometabolic Health Congress (CMHC) · Original

    Two clinical trialists discuss tirzepatide as it was in early 2023: SURPASS glycaemic results, SURMOUNT-1 weight loss, the 2.5 mg start and four-week steps, switching from a GLP-1, the oral contraceptive caution in the label and the absence of a cardiovascular outcomes trial at the time.

    Read the full fact-check

  4. 4 of 4 · 7:45

    GLP-1 Showdown: Mounjaro vs. Ozempic - Which one is right for you? | TCOYD

    Taking Control Of Your Diabetes® · Original

    Two endocrinologists from the nonprofit TCOYD compare tirzepatide and semaglutide category by category: A1c and weight favour tirzepatide in SURPASS-2, kidney and heart outcome data favour semaglutide, sleep apnoea favours tirzepatide, and both must be continued to keep the benefit.

    Read the full fact-check

Watch order and why

We put the Mayo Clinic Proceedings video first because it is short and because its fact-check teaches the most important habit for this molecule: check the label before believing a use is established. Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnoea; the study in that video is off-label and retrospective. The Endocrine Society journal club follows for viewers who want the pharmacology of dual agonism. The CMHC conversation with Dr. Juan Frias is the practical core: dose steps, switching, the contraceptive caution, cardiovascular data as of 2023. TCOYD's comparison closes by placing tirzepatide against semaglutide category by category.

Numbers to carry with you

SURMOUNT-1, 72 weeks, adults without diabetes: mean weight change of 15.0, 19.5 and 20.9 percent on 5, 10 and 15 mg against 3.1 percent on placebo (PubMed 35658024). Label escalation: 2.5 mg for four weeks, then 2.5 mg steps at least four weeks apart to a maximum of 15 mg. Most common adverse reactions in the Zepbound label: nausea 25 to 29 percent, diarrhoea 19 to 23 percent, constipation 11 to 17 percent, vomiting 8 to 13 percent, against single-digit to low-teen placebo rates.

Where these videos stop

None of the four is current on SURPASS-CVOT or SURMOUNT-5, and none discusses compounded tirzepatide, which is not FDA approved and is not interchangeable with Mounjaro or Zepbound. FormBlends dispenses compounded tirzepatide at formblends.com/products/tirzepatide and discloses that interest here. For a dated titration plan, units conversion for vials and the missed-dose rule from the label, use the Tirzepatide Hub. For every SURMOUNT and SURPASS result with confidence intervals, FormBlends Research.

Sources

  1. Zepbound (tirzepatide) prescribing information, DailyMed set id 487cd7e7-434c-4925-99fa-aa80b1cc776b Accessed September 4, 2026.
  2. Mounjaro (tirzepatide) prescribing information, DailyMed set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0 Accessed September 4, 2026.
  3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022. PubMed 35658024 Accessed September 4, 2026.

Canonical URL: https://formblendsvideos.com/playlists/tirzepatide. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.